Form S-3

Akoustis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares

Retrieved on: 
Monday, January 29, 2024
IDM, Research, Prospectus, Public expenditure, Form, Sale, Suite, Form S-3, Roth Capital Partners, Telephone, BAW, Exercise, Security (finance), Growth, Bank

Roth Capital Partners acted as sole manager for the offering.

Key Points: 
  • Roth Capital Partners acted as sole manager for the offering.
  • The offering was made pursuant to a shelf registration statement on Form S-3 (No.
  • 333-262540) that was declared effective by the Securities and Exchange Commission (the “SEC”) on February 15, 2022.
  • A final prospectus supplement and accompanying prospectus with respect to the offering has also been filed with the SEC on January 29, 2024 and is available on its website at http://www.sec.gov .

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

Retrieved on: 
Monday, January 29, 2024
Patient, Therapy, Evercore, Prospectus, Form, Lexington Avenue, Sale, Form S-3, Attention, Telephone, Equity capital markets, Security (finance), Broadridge Financial Solutions

BRISBANE, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced its plans to commence a public offering, subject to market and other conditions, to issue and sell $200.0 million of shares of its Class A common stock.

Key Points: 
  • BRISBANE, Calif., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (“Vera”), a late clinical-stage biotechnology company developing and commercializing transformative treatments for patients with serious immunologic diseases, today announced its plans to commence a public offering, subject to market and other conditions, to issue and sell $200.0 million of shares of its Class A common stock.
  • In connection with the proposed offering, Vera expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of Class A common stock sold in the public offering.
  • There can be no assurance as to whether or when the proposed offering may be completed or as to the actual size or terms of the proposed offering.
  • J.P. Morgan, TD Cowen and Evercore ISI are acting as joint book-running managers for the proposed offering.

Atlanticus Prices $50 Million Offering of Senior Notes

Retrieved on: 
Friday, January 26, 2024
Debt-to-GDP ratio, Prospectus, Form, Sale, Telephone, Suite, Form S-3, Offering, Security (finance), Egan-Jones Ratings Company, Note

ATLANTA, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Atlanticus Holdings Corporation (NASDAQ: ATLC) (“Atlanticus,” “the Company”, “we,” “our” or “us”), a financial technology company that enables its bank, retail and healthcare partners to offer more inclusive financial services to millions of everyday Americans, today announced the pricing of its underwritten registered public offering (the “Offering”) of $50 million aggregate principal amount of 9.25% Senior Notes due 2029 (the “Notes”).

Key Points: 
  • ATLANTA, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Atlanticus Holdings Corporation (NASDAQ: ATLC) (“Atlanticus,” “the Company”, “we,” “our” or “us”), a financial technology company that enables its bank, retail and healthcare partners to offer more inclusive financial services to millions of everyday Americans, today announced the pricing of its underwritten registered public offering (the “Offering”) of $50 million aggregate principal amount of 9.25% Senior Notes due 2029 (the “Notes”).
  • The Company has granted the underwriters a 30-day option to purchase up to an additional $7.5 million aggregate principal amount of the Notes in connection with the Offering.
  • The Offering is expected to close on or about January 30, 2024, subject to customary closing conditions.
  • The Company and this issuance of Notes received an “A” rating from Egan-Jones Ratings Company, an independent, unaffiliated rating agency.

Atlanticus Announces Offering of Senior Notes

Retrieved on: 
Wednesday, January 24, 2024
Senior, Prospectus, Form, Sale, Telephone, Suite, Form S-3, Offering, Security (finance), Egan-Jones Ratings Company, Note

ATLANTA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Atlanticus Holdings Corporation (NASDAQ: ATLC) (“Atlanticus,” “the Company”, “we,” “our” or “us”), a financial technology company that enables its bank, retail and healthcare partners to offer more inclusive financial services to millions of everyday Americans, today announced it has commenced an underwritten registered public offering (the “Offering”) of Senior Notes due 2029 (the “Notes”).

Key Points: 
  • ATLANTA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Atlanticus Holdings Corporation (NASDAQ: ATLC) (“Atlanticus,” “the Company”, “we,” “our” or “us”), a financial technology company that enables its bank, retail and healthcare partners to offer more inclusive financial services to millions of everyday Americans, today announced it has commenced an underwritten registered public offering (the “Offering”) of Senior Notes due 2029 (the “Notes”).
  • The Company expects to grant the underwriters a 30-day option to purchase additional Notes in connection with the Offering.
  • In connection with the Offering, the Company will apply to list the Notes on the Nasdaq Global Select Market (“Nasdaq”) under the symbol “ATLCZ.” If approved for listing, trading on Nasdaq is expected to commence within 30 business days after the Notes are first issued.
  • The Company and this issuance of Notes received an “A” rating from Egan-Jones Ratings Company, an independent, unaffiliated rating agency.

HCI Group Takes Strategic Steps to Better Position Company for Future Opportunities

Retrieved on: 
Monday, January 22, 2024
Hand, Peachtree Street, ATM, Gateway Group, Centerbridge Partners, Fifth Third Bank, Prospectus, Form, EDGAR, Sale, Form S-3, HCI, Attention, Telephone, Shelf registration, Interest, File, Security (finance)

TypTap has also redeemed all of the TypTap Series A Preferred Stock held by Centerbridge -- more than one year before Centerbridge’s optional February 26, 2025 redemption date. The redemption totaled approximately $100 million plus accrued and unpaid dividends of approximately $2.9 million. The redemption results in the elimination of any future dividends that would have otherwise accrued on the preferred shares, including dividends at the increased dividend rate of 9.5% that would have commenced in February 2024. The redemption is being funded with cash on hand, as well as approximately $50 million from HCI’s existing credit facility with Fifth Third Bank.

Key Points: 
  • TAMPA, Fla., Jan. 22, 2024 (GLOBE NEWSWIRE) -- HCI Group, Inc. (NYSE: HCI), a holding company with operations in homeowners insurance, information technology services, real estate, and reinsurance, along with its majority owned subsidiary, TypTap Insurance Group, Inc., announced today the undertaking of several strategic steps designed to increase operational and capital flexibility and to better position the company for future growth opportunities.
  • “We are taking steps to simplify our balance sheet and give us maximum flexibility to pursue attractive opportunities in the future,” said Paresh Patel, HCI’s chairman and chief executive officer.
  • HCI will recognize a one-time non-cash deemed dividend related to the warrant extension in the first quarter of 2024.
  • If you have any difficulty connecting with the conference call, please contact Gateway Group at 949-574-3860.

Perspective Therapeutics Announces Pricing of $60.0 Million Public Offering And $20.8 Million Private Placement

Retrieved on: 
Thursday, January 18, 2024
Therapy, Research, Prospectus, CATX, Form, Public expenditure, Sale, Cancer, Suite, Investment, Form S-3, Broad Street, Telephone, Attention, Exercise, Security (finance), Oppenheimer Holdings

The aggregate gross proceeds from this public offering are expected to be approximately $60.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Perspective in connection with the public offering.

Key Points: 
  • The aggregate gross proceeds from this public offering are expected to be approximately $60.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Perspective in connection with the public offering.
  • All of the shares of common stock and pre-funded warrants to be sold in the public offering are being sold by Perspective.
  • Oppenheimer & Co. and B. Riley Securities are acting as joint book-running managers for the public offering.
  • The public offering and the concurrent private placement are expected to close on or about January 22, 2024, subject to the satisfaction of customary closing conditions.

Perspective Therapeutics Announces Proposed Public Offering

Retrieved on: 
Wednesday, January 17, 2024
Therapy, Research, Perspective, Prospectus, CATX, Form, Public expenditure, Sale, Cancer, Suite, Investment, Form S-3, Broad Street, Telephone, Attention, Security (finance), Oppenheimer Holdings

In addition, Perspective intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the shares of its common stock sold in the public offering at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • In addition, Perspective intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the shares of its common stock sold in the public offering at the public offering price, less underwriting discounts and commissions.
  • All of the securities to be sold in the public offering are being offered by Perspective.
  • The proposed public offering and concurrent private placement are subject to market conditions and there can be no assurance as to whether or when the offerings may be completed, or as to the actual size or terms of the public offering or concurrent private placement.
  • The securities in the proposed public offering will be offered by means of a prospectus supplement and accompanying prospectus relating to the public offering that form a part of the registration statement.

Gevo Files New S-3 Ahead of Expiration, Updates ATM Agreement

Retrieved on: 
Tuesday, January 16, 2024
GEVO, Gevo, S-3, Form S-3, Form

Such registration statement is subject to review and being declared effective by the SEC.

Key Points: 
  • Such registration statement is subject to review and being declared effective by the SEC.
  • The Company’s current Form S-3 is set to expire this Friday, January 19th, subject to applicable grace periods.
  • Gevo filed the new S-3 as a matter of course in advance of that expiration.
  • In conjunction with the new S-3 filing, Gevo signed a new agreement for the Company’s At-the-Market (“ATM”) offering facility.

Vaxart Announces $10.0 Million Registered Direct Offering with RA Capital Management

Retrieved on: 
Tuesday, January 16, 2024
SAN, Vaxart, Prospectus, Public expenditure, Form, Public, Sale, Suite, Form S-3, Telephone, Security (finance)

SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has entered into a common stock purchase agreement with RA Capital Management for the sale of 15,384,615 shares of its common stock in a registered direct offering at an offering price of $0.65 per share.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has entered into a common stock purchase agreement with RA Capital Management for the sale of 15,384,615 shares of its common stock in a registered direct offering at an offering price of $0.65 per share.
  • Gross proceeds are approximately $10.0 million, before deducting expenses payable by Vaxart.
  • Vaxart intends to use the net proceeds from the offering primarily for general corporate purposes, including working capital, operating expenses and capital expenditures.
  • “We appreciate the financial backing by RA Capital as we continue to progress our oral pill vaccine platform,” said Dr. Michael J. Finney, Vaxart’s Interim Chief Executive Officer.

Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering

Retrieved on: 
Thursday, January 11, 2024
Nicollet Mall, Form, Sale, Form S-3, Central nervous system, Telephone, Attention, Praxis, Security (finance), CNS

The gross proceeds from the offering are expected to be approximately $150.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Praxis.

Key Points: 
  • The gross proceeds from the offering are expected to be approximately $150.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Praxis.
  • All shares and pre-funded warrants in the offering are being offered by Praxis.
  • In addition, Praxis has granted the underwriters a 30-day option to purchase up to 633,750 additional shares of common stock at the public offering price, less the underwriting discount and commission.
  • The offering is expected to close on or about January 16, 2024, subject to market conditions and the satisfaction of customary closing conditions.